Professor Ian Charles
Co-founder, Non-Executive Director and Chairman of SAB
Ian’s career spans big pharma, biotech and academia with a strong focus on translational research and infectious diseases, including vaccine and small molecule drug discovery. He is currently the Director of the Quadram Institute, which is strategically funded by the Biotechnology and Biological Sciences Research Council (BBSRC). Immediately prior to this he was Director of the ithree institute at the University of Technology Sydney (UTS) where he made discoveries that led to the formation of Auspherix, and was responsible for attracting the MRCF as an investor. Having led the Company’s R&D as CSO for the first two years and as co-founder and prior CSO of Auspherix, Ian continues to actively contribute to the Company’s scientific direction as a member of the Board and as Chair of the Advisory Board. A serial entrepreneur, he was also the co-founder and CSO of Arrow Therapeutics, an anti-infectives drug discovery company which was sold to AstraZeneca in 2007. He currently serves as Non Executive Director of Genus plc. His earlier industry career has included leading groups at the Wellcome Laboratories, UK and at Glaxo-Wellcome, with academic positions including being a founding member of the Wolfson Institute for Biomedical Research at University College London (UCL), and positions at Sheffield, Cambridge and Leicester Universities. He has a PhD in Biochemistry from the University of Leicester.